CN1066329C - 药物组合物的制备方法 - Google Patents

药物组合物的制备方法 Download PDF

Info

Publication number
CN1066329C
CN1066329C CN96107466A CN96107466A CN1066329C CN 1066329 C CN1066329 C CN 1066329C CN 96107466 A CN96107466 A CN 96107466A CN 96107466 A CN96107466 A CN 96107466A CN 1066329 C CN1066329 C CN 1066329C
Authority
CN
China
Prior art keywords
acid
formula
chemical compound
tert
decahydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CN96107466A
Other languages
English (en)
Chinese (zh)
Other versions
CN1138983A (zh
Inventor
约瑟夫·阿姆斯特朗·马丁
萨利·莱德硕
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Setters
Original Assignee
Setters
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Setters filed Critical Setters
Publication of CN1138983A publication Critical patent/CN1138983A/zh
Application granted granted Critical
Publication of CN1066329C publication Critical patent/CN1066329C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Confectionery (AREA)
  • Cleaning Or Clearing Of The Surface Of Open Water (AREA)
  • Measurement Of Force In General (AREA)
  • Hydrogenated Pyridines (AREA)
CN96107466A 1989-12-11 1990-12-10 药物组合物的制备方法 Expired - Lifetime CN1066329C (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB898927913A GB8927913D0 (en) 1989-12-11 1989-12-11 Amino acid derivatives
GB8927913.7 1989-12-11
SG120493A SG120493G (en) 1989-12-11 1993-11-02 N-tert-Butyl-decahydro-2(3-amino-2-hydroxy-4-phenyl-butyl) isoquinoline-3-carboxamide and asparaginyl derivatives thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN90109931A Division CN1034805C (zh) 1989-12-11 1990-12-10 氨基酸衍生物的制备方法

Publications (2)

Publication Number Publication Date
CN1138983A CN1138983A (zh) 1997-01-01
CN1066329C true CN1066329C (zh) 2001-05-30

Family

ID=26296345

Family Applications (2)

Application Number Title Priority Date Filing Date
CN96107466A Expired - Lifetime CN1066329C (zh) 1989-12-11 1990-12-10 药物组合物的制备方法
CN90109931A Expired - Lifetime CN1034805C (zh) 1989-12-11 1990-12-10 氨基酸衍生物的制备方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN90109931A Expired - Lifetime CN1034805C (zh) 1989-12-11 1990-12-10 氨基酸衍生物的制备方法

Country Status (48)

Country Link
US (1) US5196438A (enExample)
EP (1) EP0432695B1 (enExample)
JP (1) JP2807093B2 (enExample)
KR (1) KR970005912B1 (enExample)
CN (2) CN1066329C (enExample)
AT (1) ATE122661T1 (enExample)
AU (1) AU634319B2 (enExample)
BG (1) BG51452A3 (enExample)
BR (1) BR9006264A (enExample)
CA (1) CA2030433C (enExample)
CU (1) CU22305A3 (enExample)
CZ (1) CZ280558B6 (enExample)
DE (2) DE19675051I2 (enExample)
DK (1) DK0432695T3 (enExample)
DZ (1) DZ1467A1 (enExample)
EG (1) EG19722A (enExample)
ES (1) ES2072959T3 (enExample)
FI (2) FI100883B (enExample)
GB (2) GB8927913D0 (enExample)
GR (1) GR3017114T3 (enExample)
HK (1) HK129093A (enExample)
HR (1) HRP930341B1 (enExample)
HU (2) HU207298B (enExample)
ID (1) ID1018B (enExample)
IE (1) IE67523B1 (enExample)
IL (1) IL96550A (enExample)
IN (1) IN172553B (enExample)
IS (1) IS1803B (enExample)
LT (1) LT3682B (enExample)
LU (1) LU90014I2 (enExample)
LV (1) LV5738B4 (enExample)
MA (1) MA22014A1 (enExample)
MC (1) MC2195A1 (enExample)
MT (1) MTP1075B (enExample)
MW (1) MW8890A1 (enExample)
MX (1) MX173630B (enExample)
NL (1) NL970013I2 (enExample)
NO (1) NO176566C (enExample)
OA (1) OA09334A (enExample)
PL (1) PL165225B1 (enExample)
PT (1) PT96145B (enExample)
RO (1) RO107942B1 (enExample)
RU (1) RU2071470C1 (enExample)
SG (1) SG120493G (enExample)
SI (1) SI9012315B (enExample)
SK (1) SK280249B6 (enExample)
ZA (1) ZA909743B (enExample)
ZW (1) ZW17490A1 (enExample)

Families Citing this family (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040122000A1 (en) * 1981-01-07 2004-06-24 Vertex Pharmaceuticals Incorporated. Inhibitors of aspartyl protease
US6878728B1 (en) 1999-06-11 2005-04-12 Vertex Pharmaceutical Incorporated Inhibitors of aspartyl protease
US5614533A (en) * 1987-03-13 1997-03-25 Bio-Mega/Boehringer Ingelheim Research, Inc. Substituted pipecolinic acid derivatives as HIV protease inhibitors
USH1649H (en) 1987-07-31 1997-05-06 Barrish; Joel C. HIV protease inhibitor combinations
CA1340588C (en) * 1988-06-13 1999-06-08 Balraj Krishan Handa Amino acid derivatives
GB8927915D0 (en) * 1989-12-11 1990-02-14 Hoffmann La Roche Novel alcohols
US5430041A (en) * 1991-05-10 1995-07-04 Hoffmann-La Roche Inc. Amino acid derivatives having antiviral activity
CN1071930A (zh) * 1991-07-10 1993-05-12 伊莱利利公司 用作治疗艾滋病的人免疫缺陷病毒蛋白酶的抑制剂
US5508407A (en) * 1991-07-10 1996-04-16 Eli Lilly And Company Retroviral protease inhibitors
WO1993008184A1 (en) * 1991-10-23 1993-04-29 Merck & Co., Inc. Hiv protease inhibitors
US5413999A (en) * 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
DK0541168T3 (da) * 1991-11-08 1998-05-11 Merck & Co Inc HIV-proteaseinhibitorer, som er egnede til behandling af AIDS
BR9306058A (pt) 1992-03-11 1997-11-18 Narhex Ltd Derivados de amina de hidrocarbonetos oxo- e hidroxi- substituidos
US5888992A (en) 1992-03-11 1999-03-30 Narhex Limited Polar substituted hydrocarbons
US6071895A (en) 1992-03-11 2000-06-06 Narhex Limited Polar-substituted hydrocarbons
ATE116640T1 (de) * 1992-03-13 1995-01-15 Bio Mega Boehringer Ingelheim Substituierte pipecoline-säurederivate als hiv- protease-hemmer.
EP0641325B1 (en) * 1992-05-21 2001-03-07 Monsanto Company Retroviral protease inhibitors
US5559256A (en) * 1992-07-20 1996-09-24 E. R. Squibb & Sons, Inc. Aminediol protease inhibitors
DE122007000045I2 (de) 1992-08-25 2011-07-21 Gd Searle Llc Gd Searle Llc Darunavir oder pharmazeutisch vertragliche Salze, Hydroxyethylaminosulfonamide verwendbar als InhibiEster oder Prodrugs davon. toren retroviraler Proteasen.
IS2334B (is) 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
US5783701A (en) 1992-09-08 1998-07-21 Vertex Pharmaceuticals, Incorporated Sulfonamide inhibitors of aspartyl protease
US5723490A (en) * 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease
TW372972B (en) * 1992-10-23 1999-11-01 Novartis Ag Antiretroviral acyl compounds
US5380849A (en) * 1992-11-09 1995-01-10 Merck & Co., Inc. Process for optically pure decahydroisoqiunolines
US5430150A (en) * 1992-12-16 1995-07-04 American Cyanamid Company Retroviral protease inhibitors
US5434265A (en) * 1992-12-22 1995-07-18 Eli Lilly And Company Inhibitors of HIV protease
MX9308025A (es) * 1992-12-22 1994-08-31 Lilly Co Eli Compuestos inhibidores de la proteasa del virus dela inmunodeficiencia humana, procedimiento para supreparacion y formulacion farmaceutica que los contiene.
US5491166A (en) * 1992-12-22 1996-02-13 Eli Lilly And Company Inhibitors of HIV protease useful for the treatment of AIDS
MX9308016A (es) * 1992-12-22 1994-08-31 Lilly Co Eli Compuestos inhibidores de la proteasa del virus de la inmunodeficiencia humana, procedimiento para su preparacion y formulacion farmaceutica que los contiene.
US5484926A (en) * 1993-10-07 1996-01-16 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
US5733906A (en) * 1993-10-12 1998-03-31 Eli Lilly And Company Inhibitors of HIV Protease useful for the treatment of Aids
US5846993A (en) * 1992-12-22 1998-12-08 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
US5693815A (en) * 1993-01-17 1997-12-02 Schering Corporation Peptides
US5939430A (en) * 1993-02-22 1999-08-17 Merrell Pharmaceuticals Inc. Combinations of retroviral inhibitors
US5455353A (en) * 1993-03-24 1995-10-03 Hoffmann-La Roche Inc. 4-(benzyl-2-oxo-oxazolidin-5 ylmethyl)N tertbutyl-decahydroisoquinoline-3-carboxamides
ATE149162T1 (de) * 1993-07-15 1997-03-15 Hoffmann La Roche Verfahren zur herstellung eines n- tert.butylisochinolin-3-carboxamid derivates und zwischenprodukte in diesem verfahren
DE69426655T2 (de) * 1994-02-02 2001-06-13 Eli Lilly And Co., Indianapolis Hiv-protease inhibitoren und zwischenprodukte
MX9603909A (es) * 1994-03-07 1997-03-29 Vertex Pharma Derivados de sulfonamida como inhibidores de proteasa aspartilo.
US5527829A (en) * 1994-05-23 1996-06-18 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
US5470979A (en) * 1994-07-01 1995-11-28 American Cyanamid Company Asymmetric synthesis of bicyclic amino acid esters
US5591885A (en) * 1994-09-23 1997-01-07 Hoffman-La Roche Inc. Process for the preparation of halogenated α-aminoketone compounds
US5523463A (en) * 1994-09-23 1996-06-04 Hoffmann-La Roche Inc. Method of producing halogenated and alpha-aminoalchohols
US5691372A (en) * 1995-04-19 1997-11-25 Vertex Pharmaceuticals Incorporated Oxygenated-Heterocycle containing sulfonamide inhibitors of aspartyl protease
US6008228A (en) * 1995-06-06 1999-12-28 Hoffman-La Roche Inc. Pharmaceutical compositions containing proteinase inhibitors
ES2182996T3 (es) * 1995-06-06 2003-03-16 Hoffmann La Roche Composiciones farmaceuticas que comprenden un inhibidor de proteinasa y un monglicerido.
US6004957A (en) * 1995-06-07 1999-12-21 Vertex Pharmaceuticals, Incorporated Sulfonamide inhibitors of aspartyl protease
AU759386B2 (en) * 1995-06-29 2003-04-10 Abbvie Inc. Use of Ritonavir (ABT-538) for improving the pharmacokinetics of drugs metabolized by cytochrome P450 in a method of treating AIDS
US6037157A (en) 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
DK0861085T3 (da) 1995-11-13 2005-11-21 Vitaleech Bioscience N V Antivirale isolater opnået fra igler
US5914332A (en) 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
US5883252A (en) * 1996-01-26 1999-03-16 Vertex Pharmaceuticals Incorporated Aspartyl protease inhibitors
US5587481A (en) * 1996-02-20 1996-12-24 The Monsanto Company Preparation of (S)-decahydroisoquinoline-3-carboxylic acid t-butylamide
US5914404A (en) * 1996-08-09 1999-06-22 Hoffmann-La Roche Inc. Process for the preparation of quinargine
EP0823424A1 (de) * 1996-08-09 1998-02-11 F. Hoffmann-La Roche Ag Verfahren zur Herstellung von Chinargin
US5705647A (en) * 1996-09-05 1998-01-06 Agouron Pharmaceuticals, Inc. Intermediates for making HIV-protease inhibitors
US5925759A (en) 1996-09-05 1999-07-20 Agouron Pharmaceuticals, Inc. Methods of making HIV-protease inhibitors and intermediates for making HIV-protease inhibitors
US5962725A (en) 1996-09-05 1999-10-05 Agouron Pharmaceuticals, Inc. Intermediate compounds useful for making HIV protease inhibitors such as nelfinavir
US6232333B1 (en) 1996-11-21 2001-05-15 Abbott Laboratories Pharmaceutical composition
DK0847994T3 (da) 1996-12-11 2003-07-28 Hoffmann La Roche Fremgangsmåde til fremstilling af blandede anhydrider
US6001851A (en) * 1997-03-13 1999-12-14 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
US6084107A (en) * 1997-09-05 2000-07-04 Agouron Pharmaceuticals, Inc. Intermediates for making HIV-protease inhibitors
US6143742A (en) * 1997-12-11 2000-11-07 Fuisz Technologies Ltd Treatment for necrotizing infections
US6436989B1 (en) * 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
FR2779653B1 (fr) * 1998-06-11 2002-12-20 Inst Nat Sante Rech Med Utilisation de composes modulateurs du proteasome en therapie
BR9912169A (pt) * 1998-06-19 2001-04-10 Vertex Pharma Inibidores de sulfonamida de protease de aspartil
EP1123288A1 (en) * 1998-10-21 2001-08-16 Fujisawa Pharmaceutical Co., Ltd. Vitreous form of known bradykinin antagonist
KR100277723B1 (ko) 1998-12-14 2001-01-15 남창우 광학적으로 순수한 데카하이드로이소퀴놀린카르복사미드의 연속제조공정
US7635690B2 (en) * 1999-01-22 2009-12-22 Emory University HIV-1 mutations selected for by β-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine
US7115584B2 (en) * 1999-01-22 2006-10-03 Emory University HIV-1 mutations selected for by β-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine
US6765019B1 (en) 1999-05-06 2004-07-20 University Of Kentucky Research Foundation Permeable, water soluble, non-irritating prodrugs of chemotherapeutic agents with oxaalkanoic acids
PT1183026E (pt) * 1999-06-04 2006-11-30 Abbott Lab Formulações farmacêuticas melhoradas incluindo ritonavir
CA2375954A1 (en) * 1999-07-20 2001-01-25 Mark Charest Alpha-hydroxy-gamma-¬¬(carbocyclic-or heterocyclic-substituted)amino|carbonyl|alkanamide derivatives and uses thereof
US6589962B1 (en) 1999-07-20 2003-07-08 Merck & Co., Inc. Alpha-hydroxy-gamma-[[(carbocyclic-or heterocyclic-substituted)amino]carbonyl]alkanamide derivatives and uses thereof
ES2295068T3 (es) 1999-11-24 2008-04-16 MERCK & CO., INC. Gamma-hidroxi-2-(fluoroalquilaminocarbonil)-1-piperazinpentanamidas como inhibidores de la proteasa del vih.
IT1313682B1 (it) * 1999-11-25 2002-09-09 Archimica Spa Procedimento per la preparazione di (s)-n-terbutil-1,2,3,4-tetraidroisochinolin-3-carbossiammide.
ES2676151T3 (es) 2000-01-19 2018-07-17 Abbvie Inc. Formulaciones farmacéuticas mejoradas
AU2001259817A1 (en) 2000-05-04 2001-11-12 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, The National Institutes Of Health Methods of and compounds for inhibiting calpains
IT1318986B1 (it) * 2000-10-09 2003-09-19 Archimica S P A Ora Clariant L Procedimento per la preparazione di (s)-n-terbutil-1,2,3,4-tetraidroisochinolin-3-carbossiammide.
GB0028483D0 (en) 2000-11-22 2001-01-10 Hoffmann La Roche Hydroxyethylamine HIV protease inhibitors
US20030191121A1 (en) * 2001-08-09 2003-10-09 Miller Ross A. Piperazine carboxamide intermediates of HIV protease inhibitors and processes for their preparation
WO2003054155A2 (en) 2001-12-19 2003-07-03 Bristol-Myers Squibb Company Pichia pastoris formate dehydrogenase and uses therefor
US20040067216A1 (en) * 2002-02-22 2004-04-08 Karki Shyam B. Hiv protease inhibitors supported on cation exchange resins for oral administration
EP2316468A1 (en) 2002-02-22 2011-05-04 Shire LLC Delivery system and methods for protecting and administering dextroamphetamine
US7157489B2 (en) * 2002-03-12 2007-01-02 The Board Of Trustees Of The University Of Illinois HIV protease inhibitors
US7115652B2 (en) * 2002-06-17 2006-10-03 Sunesis Pharmaceuticals, Inc. Aspartyl protease inhibitors
AU2003276047A1 (en) * 2002-06-17 2003-12-31 Sunesis Pharmaceuticals, Inc. Aspartyl protease inhibitors
KR100767271B1 (ko) * 2003-07-11 2007-10-17 에프. 호프만-라 로슈 아게 사퀴나비르 메실레이트 경구 투여 형태
EP1604662A1 (en) * 2004-06-08 2005-12-14 Santhera Pharmaceuticals (Deutschland) Aktiengesellschaft 1-[(3R)-Amino-4-(2-fluoro-phenyl)-butyl]-pyrrolidine-(2R)-carboxylic acid benzyl amine derivatives and related compounds as dipeptidyl peptidase IV (DPP-IV) inhibitors for the treatment of type 2 diabetes mellitus
PT2258376T (pt) 2004-07-27 2019-05-31 Gilead Sciences Inc Análogos fosfonatados de compostos inibidores do vih
WO2006134612A1 (en) * 2005-06-16 2006-12-21 Hetero Drugs Limited A process for the preparation of saquinavir using novel intermediate
WO2008112289A2 (en) 2007-03-12 2008-09-18 Nektar Therapeutics Oligomer-protease inhibitor conjugates
WO2009006203A1 (en) * 2007-06-29 2009-01-08 Gilead Sciences, Inc. Therapeutic compositions and the use thereof
SG182229A1 (en) * 2007-06-29 2012-07-30 Gilead Sciences Inc Therapeutic compositions and the use thereof
EP2203420A1 (en) * 2007-09-25 2010-07-07 Merck Sharp & Dohme Corp. Hiv protease inhibitors
WO2009114151A1 (en) * 2008-03-12 2009-09-17 Nektar Therapeutics Oligomer-amino acid and olgomer-atazanavir conjugates
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
UY32306A (es) 2008-12-09 2010-07-30 Gilead Sciences Inc Derivados de pteridinona y pirimidinodiazepinona y composiciones farmacéuticas que modulan en forma selectiva los receptores tipo toll, métodos y usos
CL2009002206A1 (es) 2008-12-23 2011-08-26 Gilead Pharmasset Llc Compuestos derivados de pirrolo -(2-3-d]-pirimidin-7(6h)-tetrahidrofuran-2-il fosfonamidato, composicion farmaceutica; y su uso en el tratamiento de enfermedades virales.
AR074897A1 (es) * 2008-12-23 2011-02-23 Pharmasset Inc Fosforamidatos de nucleosidos
MX2011006890A (es) * 2008-12-23 2011-07-20 Pharmasset Inc Analogos de nucleosidos.
CA2762582A1 (en) 2009-05-27 2010-12-02 Merck Sharp & Dohme Corp. Hiv protease inhibitors
EP2440249A2 (en) 2009-06-12 2012-04-18 Nektar Therapeutics Covalent conjugates comprising a protease inhibitor, a water-soluble, non-peptidic oligomer and a lipophilic moiety
DE102010004957A1 (de) 2010-01-14 2011-07-21 Universitätsklinikum Jena, 07743 Biologisch wirksame Moleküle zur Beeinflussung von Virus-, Bakterien-, Parasiten-infizierten Zellen und/oder Tumorzellen und Verfahren zu deren Anwendung
US20110223131A1 (en) 2010-02-24 2011-09-15 Gilead Sciences, Inc. Antiviral compounds
AP2012006535A0 (en) 2010-03-31 2012-10-31 Gilead Pharmasset Llc Stereoselective synthesis of phosphorous containing actives
US9079834B2 (en) 2010-10-28 2015-07-14 Merck Canada Inc. HIV protease inhibitors
EP2392926A1 (en) 2011-02-09 2011-12-07 Roche Diagnostics GmbH Urinary biomarkers in HIV infected subjects
US9133157B2 (en) 2011-10-26 2015-09-15 Merck Canada Inc. HIV protease inhibitors
IN2012DE00082A (enExample) 2012-01-10 2015-05-01 Council Scient Ind Res
JP2015527403A (ja) 2012-09-11 2015-09-17 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｈｉｖプロテアーゼ阻害剤
US9227990B2 (en) 2012-10-29 2016-01-05 Cipla Limited Antiviral phosphonate analogues and process for preparation thereof
WO2015013835A1 (en) 2013-07-31 2015-02-05 Merck Sharp & Dohme Corp. Piperazine derivatives as hiv protease inhibitors
WO2015095265A1 (en) 2013-12-19 2015-06-25 Merck Sharp & Dohme Corp. Hiv protease inhibitors
WO2015095276A1 (en) 2013-12-19 2015-06-25 Merck Sharp & Dohme Corp. Hiv protease inhibitors
US9994587B2 (en) 2014-03-06 2018-06-12 Merck Sharp & Dohme Corp. HIV protease inhibitors
WO2015138220A1 (en) 2014-03-10 2015-09-17 Merck Sharp & Dohme Corp. Piperazine derivatives as hiv protease inhibitors
WO2016001907A1 (en) 2014-07-02 2016-01-07 Prendergast Patrick T Mogroside iv and mogroside v as agonist/stimulator/un-blocking agent for toll-like receptor 4 and adjuvant for use in human/animal vaccine and to stimulate immunity against disease agents.
SI3166607T1 (sl) 2014-07-11 2023-01-31 Gilead Sciences, Inc. Modulatorji toličnih receptorjev za zdravljenje HIV-a
US9738664B2 (en) 2014-10-29 2017-08-22 Wisconsin Alumni Research Foundation Boronic acid inhibitors of HIV protease
US20180263985A1 (en) 2015-09-15 2018-09-20 Gilead Sciences, Inc. Modulators of toll-like receptors for the treatment of hiv
WO2021209563A1 (en) 2020-04-16 2021-10-21 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0190058A1 (fr) * 1985-01-07 1986-08-06 Adir Nouveaux dérivés peptidiques à structure polycyclique azotée, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
EP0282374A1 (fr) * 1987-02-13 1988-09-14 Adir Et Compagnie Nouveaux dérivés peptidiques à structure polycyclique azotée, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB933968A (en) * 1960-10-26 1963-08-14 May & Baker Ltd New phthalimide derivatives
US4123543A (en) * 1971-09-16 1978-10-31 Ab Kabi Derivatives of substituted indoline lactans with effect on the central nervous system
US3901897A (en) * 1972-10-05 1975-08-26 Squibb & Sons Inc 1,2,3,4,4a,5,6,7-octahydro-7-aryl-isoquinolines and derivatives thereof
US4329473A (en) * 1979-06-01 1982-05-11 Almquist Ronald G Oxoalkanoic acid derivatives as inhibitors of angiotensin converting enzyme
SE421551B (sv) * 1980-03-26 1982-01-04 Sandvik Ab Borrverktyg for rotations- och/eller slagborrning
US4470973A (en) * 1982-07-19 1984-09-11 E. R. Squibb & Sons, Inc. Substituted peptide compounds
US4812442A (en) * 1984-05-29 1989-03-14 Merck & Co., Inc. Tripeptide renin inhibitors
AT383762B (de) * 1985-12-23 1987-08-25 Plansee Metallwerk Verfahren zur herstellung mehrkomponentiger, kongruent erschmelzender lotmaterialien
CA1286989C (en) * 1985-12-26 1991-07-30 A. Arthur Gottlieb Immunoamplifiers and related compositions
WO1988000939A1 (fr) * 1986-07-25 1988-02-11 Banyu Pharmaceutical Co., Ltd. Derives d'amino-alcools optiquement actifs et procede pour leur preparation
EP0264106B1 (en) * 1986-10-14 1994-03-16 Banyu Pharmaceutical Co., Ltd. 5-Substituted amino-4-hydroxy-pentanoic acid derivatives and their use
US4863905A (en) * 1987-02-04 1989-09-05 Warner-Lambert Company Renin inhibitors II
DE3717631A1 (de) * 1987-05-26 1988-12-15 Merck Patent Gmbh Aminosaeurederivate
DE3733296A1 (de) * 1987-10-02 1989-04-20 Merck Patent Gmbh Aminosaeurederivate
IL89900A0 (en) * 1988-04-12 1989-12-15 Merck & Co Inc Hiv protease inhibitors useful for the treatment of aids and pharmaceutical compositions containing them
CA1340588C (en) * 1988-06-13 1999-06-08 Balraj Krishan Handa Amino acid derivatives
DE4033062A1 (de) * 1990-10-18 1992-04-23 Merck Patent Gmbh Aminosaeurederivate
GB8927915D0 (en) * 1989-12-11 1990-02-14 Hoffmann La Roche Novel alcohols

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0190058A1 (fr) * 1985-01-07 1986-08-06 Adir Nouveaux dérivés peptidiques à structure polycyclique azotée, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
EP0282374A1 (fr) * 1987-02-13 1988-09-14 Adir Et Compagnie Nouveaux dérivés peptidiques à structure polycyclique azotée, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
ZA909743B (en) 1991-08-28
US5196438A (en) 1993-03-23
NL970013I2 (nl) 1997-09-01
LU90014I2 (fr) 1997-01-31
NO176566B (no) 1995-01-16
DE69019481T2 (de) 1995-11-09
GR3017114T3 (en) 1995-11-30
GB9026776D0 (en) 1991-01-30
GB8927913D0 (en) 1990-02-14
CA2030433A1 (en) 1991-06-12
DE69019481D1 (de) 1995-06-22
GB2239016A (en) 1991-06-19
SK576590A3 (en) 1999-10-08
HUT56073A (en) 1991-07-29
IS3651A7 (is) 1991-06-12
LV5738B4 (lv) 1996-12-20
ID1018B (id) 1996-10-18
HU207298B (en) 1993-03-29
PL288201A1 (en) 1991-09-09
SG120493G (en) 1994-01-21
EP0432695B1 (en) 1995-05-17
EP0432695A3 (en) 1991-12-18
BR9006264A (pt) 1991-09-24
DE19675051I2 (de) 2001-04-12
LT3682B (en) 1996-01-25
CN1034805C (zh) 1997-05-07
GB2239016B (en) 1993-08-04
FI973895A7 (fi) 1997-10-06
SI9012315B (sl) 1998-06-30
HU211342A9 (en) 1995-11-28
RO107942B1 (ro) 1994-01-31
OA09334A (fr) 1992-09-15
EG19722A (en) 1996-01-31
MTP1075B (en) 1991-07-31
LTIP862A (en) 1995-03-27
JP2807093B2 (ja) 1998-09-30
PT96145B (pt) 1998-04-30
PL165225B1 (pl) 1994-11-30
ATE122661T1 (de) 1995-06-15
AU634319B2 (en) 1993-02-18
AU6787690A (en) 1991-06-13
KR910011894A (ko) 1991-08-07
NO905322L (no) 1991-06-12
DK0432695T3 (da) 1995-09-11
MA22014A1 (fr) 1991-07-01
HK129093A (en) 1993-12-03
LV5738A4 (lv) 1996-08-20
HRP930341B1 (en) 1998-12-31
FI905983L (fi) 1991-06-12
ES2072959T3 (es) 1995-08-01
CZ576590A3 (en) 1995-11-15
MX173630B (es) 1994-03-18
CZ280558B6 (cs) 1996-02-14
CA2030433C (en) 1997-10-21
FI973895A0 (fi) 1997-10-06
DZ1467A1 (fr) 2004-09-13
PT96145A (pt) 1991-09-30
EP0432695A2 (en) 1991-06-19
HRP930341A2 (en) 1994-10-31
BG51452A3 (bg) 1993-05-14
IL96550A0 (en) 1991-09-16
IS1803B (is) 2002-02-26
ZW17490A1 (en) 1992-06-17
MX23619A (es) 1993-10-01
FI905983A0 (fi) 1990-12-04
CU22305A3 (es) 1995-01-31
HU908076D0 (en) 1991-06-28
IE904453A1 (en) 1991-06-19
NO176566C (no) 1995-04-26
NO905322D0 (no) 1990-12-10
SI9012315A (en) 1997-10-31
IE67523B1 (en) 1996-04-03
IL96550A (en) 1995-03-15
NL970013I1 (nl) 1997-05-01
MW8890A1 (en) 1991-03-13
MC2195A1 (fr) 1992-10-05
RU2071470C1 (ru) 1997-01-10
CN1138983A (zh) 1997-01-01
FI973895L (fi) 1997-10-06
SK280249B6 (sk) 1999-10-08
FI100883B (fi) 1998-03-13
IN172553B (enExample) 1993-09-25
JPH03255076A (ja) 1991-11-13
KR970005912B1 (en) 1997-04-22
CN1052482A (zh) 1991-06-26

Similar Documents

Publication Publication Date Title
CN1052482A (zh) 氨基酸衍生物
US5296604A (en) Proline derivatives and compositions for their use as inhibitors of HIV protease
RU2130016C1 (ru) Производные сукциноиламиногидроксиэтиламиносульфонамида, фармацевтическая композиция, способ ингибирования ретровирусной протеазы, способ лечения ретровирусной инфекции, способ лечения вич-инфекции
US4294832A (en) Tetrahydroisoquinoline compounds and a pharmaceutical composition thereof
KR910003348B1 (ko) 펩티딜아미노 디올
JPH02191243A (ja) 製剤学的活性を有する化合物
EP0337714A2 (en) HIV protease inhibitors useful for the treatment of aids
KR0173034B1 (ko) 선택적 트롬빈 억제제
DE60221508T2 (de) Aminosäurederivate als hiv-protease-inhibitoren
CN112592331A (zh) 一种奥司他韦protac化合物及其制备方法与在抗流感病毒药物中的应用
JPH11503422A (ja) プロテアーゼを阻害するコハク酸誘導体
JPS6323897A (ja) タフトシン類似体、その製法及び医薬組成物
CN1168673A (zh) 具有n-末端磺酰基或氨基磺酰基的新颖二肽对-脒基苄基酰胺
WO2000059867A1 (en) Hydroxyphenyl derivatives with hiv integrase inhibitory properties
JPH07502255A (ja) 抗ウイルス化合物類
EP0261017B1 (fr) Esters d'aminoacides d'alcools cycloaliphatiques, procédé de préparation et utilisation comme médicaments
JPH04334349A (ja) ３−クロロ−２−クロロメチル−１−プロペンから誘導されたレトロウイルスのプロテアーゼ阻害因子
JPH02218654A (ja) 安息香酸誘導体、それらの製造方法およびそれらを含有する薬剤
JPH04275263A (ja) キラルα−アミノアルデヒドからの、ヒドロキシエステル、ヒドロキシアミド及びラクトン化合物の立体制御された製造法
CN112500308B (zh) 金色酰胺醇酯及其氟化衍生物及制备方法和应用
US6362165B1 (en) Hydroxyphenyl derivatives with HIV integrase inhibitory properties
US4324916A (en) Decaprenylamine derivatives
EP0575500A1 (en) Hiv protease inhibitors
EP4724423A1 (en) Solid forms of n-(methoxycarbonyl)-3-methyl-l-valyl-(4 r)- n-{(1 s)-1-cyano-2-[(3 s)-2-oxopyrrolidin-3-yl]ethyl}-4-(trifluoromethyl)-l-prolinamide and solvates thereof
CA2302144A1 (en) Hydroxyphenyl derivatives with hiv integrase inhibitory properties

Legal Events

Date Code Title Description
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C06 Publication
PB01 Publication
C14 Grant of patent or utility model
GR01 Patent grant
C15 Extension of patent right duration from 15 to 20 years for appl. with date before 31.12.1992 and still valid on 11.12.2001 (patent law change 1993)
OR01 Other related matters
C17 Cessation of patent right
CX01 Expiry of patent term

Expiration termination date: 20101210

Granted publication date: 20010530